menu
    • menu
    [{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"INX-315","moa":"CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyclix Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Inapplicable"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Boxer Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"INX-315","moa":"CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyclix Bio \/ Boxer Capital","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Boxer Capital"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INX-315","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyclix Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Inapplicable"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"INX-315","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyclix Bio \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Eli Lilly"}]

    Find Clinical Drug Pipeline Developments & Deals by Incyclix Bio

    Menu

    Incyclix Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Incyclix Bio

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Incyclix Bio

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INX-315,Abemaciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Incyclix Shares Interim Phase 1/2 Data of INX-315 in CDK4/6 Resistant Breast Cancer

                            Details : INX-315 is a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio (abemaciclib) and fulvestrant for the treatment of HR+/HER2- Breast Cancer.

                            Product Name : INX-315

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 13, 2024

                            Lead Product(s) : INX-315,Abemaciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Incyclix Bio

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Incyclix Bio

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INX-315,Abemaciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Incyclix Bio Collaborates with Lilly to Evaluate INX-315 in HR+/HER2- Breast Cancer

                            Details : The collaboration aims to evaluate INX-315, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio (abemaciclib) and fulvestrant in HR+/HER2- Breast Cancer.

                            Product Name : INX-315

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 18, 2024

                            Lead Product(s) : INX-315,Abemaciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Incyclix Bio

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Incyclix Bio

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INX-315

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Incyclix Bio Announces FDA Clearance of Investigational New Drug Application for INX-315 in Patients with Adva...

                            Details : INX-315 is a novel, potent and selective inhibitor of CDK2 to treat patients whose tumors are insensitive to CDK4/6 inhibition, either by primary resistance or acquired resistance due to prior treatment with a CDK4/6 inhibitor.

                            Product Name : INX-315

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 28, 2023

                            Lead Product(s) : INX-315

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Incyclix Bio

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Incyclix Bio

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INX-315

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Boxer Capital

                            Deal Size : $30.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital

                            Details : Proceeds from the financing will be used to support the clinical development of Incyclix Bio’s lead compound, INX-315, a novel, potent and selective CDK2 inhibitor with compelling preclinical efficacy and safety data.

                            Product Name : INX-315

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 31, 2022

                            Lead Product(s) : INX-315

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Boxer Capital

                            Deal Size : $30.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth